Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TOLTERODINE
PCO Manufacturing
2 Milligram
Capsule
2006-03-31
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Detrusitol® SR 2mg Prolonged Release Capsules. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 2mg tolterodine tartrate. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Prolonged release capsule, hard Green, two-piece prolonged release capsules with “2” printed on one half and a symbol on the other half. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Detrusitol SR is indicated for the treatment of urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with unstable bladder. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ADULTS (INCLUDING THE ELDERLY):_ The recommended dose is 4 mg once daily except in patients with impaired liver function or severely impaired renal function (GFR < 30 ml/min) for whom the recommended dose is 2 mg once daily _(see sections 4.4 and 5.2). _In case of troublesomeside-effects the dose may be reduced from 4 mg to 2 mg once daily. The prolonged-release capsules can be taken with or without food and must be swallowed whole. The effect of treatment should be re-evaluated after 2-3 months _(see section 5.1)._ _CHILDREN:_ Safety and effectiveness in children have not yet been established. Therefore Detrusitol SR prolonged-release capsules are not recommended for children, until more information is available. 4.3 CONTRAINDICATIONS Tolterodine is contraindicated in patients with o Urinary retention o Uncontrolled narrow angle glaucoma o Myasthenia gravis o Known hypersensitivity to tolterodine or excipients o Severe ulcerative colitis o Toxic megacolon IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 08/05/2009_ _CRN 2065531_ _page number: 1_ 4.4 Read the complete document